Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Tohoku journal of experimental medicine

• Publication date

  2012-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1620/TJEM.228.305PMID 23124103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats

  2014cited by this paper
• Olmesartan Medoxomil Is Associated with Decreased Plasma AGEs, Pentosidine, and N-(Epsilon)-Carboxymethyl-Lysine Levels in Hemodialysis Patients

  2012cited by this paper
• Mechanisms for enhanced endothelium-derived hyperpolarizing factor-mediated responses in microvessels in mice.

  2012cited by this paper
• Essential Role of Bone Marrow for Microvascular Endothelial and Metabolic Functions in Mice

  2012cited by this paper
• [Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo Medical University].

  2012influential reference
• Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats.

  2012cited by this paper
• Protective effects of recombinant human erythropoietin against pressure overload-induced left ventricular remodeling and premature death in mice.

  2011cited by this paper
• Hydralazine for essential hypertension.

  2011cited by this paper
• Redox Regulation of Protein Kinases as a Modulator of Vascular Function

  2011cited by this paper
• Olmesartan, an AT1 Antagonist, Attenuates Oxidative Stress, Endoplasmic Reticulum Stress and Cardiac Inflammatory Mediators in Rats with Heart Failure Induced by Experimental Autoimmune Myocarditis

  2011cited by this paper
• Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J).

  2011cited by this paper
• Calcium Channel Blocker Inhibition of AGE and RAGE Axis Limits Renal Injury in Nondiabetic Patients With Stage I or II Chronic Kidney Disease

  2011influential reference
• Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria

  2011cited by this paper
• Hydralazine for essential hypertension.

  2010cited by this paper
• Heart failure, chronic kidney disease, and biomarkers--an integrated viewpoint--.

  2010cited by this paper
• S100B Interaction With the Receptor for Advanced Glycation End Products (RAGE): A Novel Receptor-Mediated Mechanism for Myocyte Apoptosis Postinfarction

  2010cited by this paper
• OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization.

  2010cited by this paper
• Heart Failure, Chronic Kidney Disease, and Biomarkers

  2010cited by this paper
• Inflammation in atherosclerosis: transition from theory to practice.

  2010cited by this paper
• Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.

  2010cited by this paper
• Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.

  2010cited by this paper
• Endothelial Nitric Oxide Synthase–Independent Protective Action of Statin Against Angiotensin II–Induced Atrial Remodeling via Reduced Oxidant Injury

  2010cited by this paper
• Mechanisms of tissue injury in renal artery stenosis: ischemia and beyond.

  2009cited by this paper
• Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.

  2009cited by this paper
• A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study

  2009cited by this paper
• Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.

  2009cited by this paper
• Azelnidipine and Amlodipine Anti-Coronary Atherosclerosis Trial in Hypertensive Patients Undergoing Coronary Intervention by Serial Volumetric Intravascular Ultrasound Analysis in Juntendo University (ALPS-J)

  2009cited by this paper
• Endothelial dysfunction: the first step toward coronary arteriosclerosis.

  2009influential reference
• Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.

  2009cited by this paper
• Macrophage diversity in renal injury and repair.

  2008cited by this paper
• Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.

  2008cited by this paper
• Olmesartan Prevents Cardiovascular Injury and Hepatic Steatosis in Obesity and Diabetes, Accompanied by Apoptosis Signal Regulating Kinase-1 Inhibition

  2008cited by this paper
• Abstract 3629: Crucial Role of Nitric Oxide Synthases System in Endothelium-Dependent Hyperpolarization in Mice

  2008cited by this paper
• Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.

  2008cited by this paper
• Life history of eNOS: partners and pathways.

  2007cited by this paper
• Obesity induces a phenotypic switch in adipose tissue macrophage polarization.

  2007cited by this paper
• Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.

  2007cited by this paper
• Telmisartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Advanced Glycation End-product (AGE)-induced Monocyte Chemoattractant Protein-1 Expression in Mesangial Cells through Downregulation of Receptor for AGEs via Peroxisome Proliferator-activated Receptor-γ Activation

  2007cited by this paper
• Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation

  2006cited by this paper
• Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice.

  2006cited by this paper
• Rapid Communication: Blockade of Angiotensin II Receptors Reduces the Expression of Receptors for Advanced Glycation End Products in Human Endothelial Cells

  2006cited by this paper
• Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice

  2005influential reference
• Inhibitory Effects of AT1 Receptor Blocker, Olmesartan, and Estrogen on Atherosclerosis Via Anti-Oxidative Stress

  2005cited by this paper
• A Review of the Structural and Functional Features of Olmesartan Medoxomil, An Angiotensin Receptor Blocker

  2005influential reference
• Influence of Diabetes Mellitus, Hypercholesterolemia, and Their Combination on EDHF-Mediated Responses in Mice

  2005cited by this paper
• Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation

  2004cited by this paper
• Dysfunction of Endothelial Nitric Oxide Synthase and Atherosclerosis

  2004cited by this paper
• Calcium Channel Blocker Azelnidipine Enhances Vascular Protective Effects of AT1 Receptor Blocker Olmesartan

  2004cited by this paper
• Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan

  2004cited by this paper
• Chemokines in the pathogenesis of vascular disease.

  2004cited by this paper
• Dysfunction of endothelial nitric oxide synthase and atherosclerosis.

  2004cited by this paper
• Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.

  2003influential reference
• Obesity is associated with macrophage accumulation in adipose tissue.

  2003cited by this paper
• Compensatory Phosphorylation and Protein-Protein Interactions Revealed by Loss of Function and Gain of Function Mutants of Multiple Serine Phosphorylation Sites in Endothelial Nitric-oxide Synthase*

  2003cited by this paper
• Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.

  2003cited by this paper
• Rho GTPase/Rho Kinase Negatively Regulates Endothelial Nitric Oxide Synthase Phosphorylation through the Inhibition of Protein Kinase B/Akt in Human Endothelial Cells

  2002cited by this paper
• Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE.

  2001influential reference
• The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells.

  2000cited by this paper
• The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells*

  2000cited by this paper
• The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanisms.

  2000cited by this paper
• Primary endothelial dysfunction: atherosclerosis.

  1999cited by this paper
• Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.

  1999cited by this paper

• Effect of Hydralazine on Angiotensin II-Induced Abdominal Aortic Aneurysm in Apolipoprotein E-Deficient Mice

  2023cites this paper
• Anti-Inflammatory Effect of Centella asiatica Extract on Prevented Aortic Intima-Media Thickening in Diabetic Rats

  2018cites this paper
• Azelnidipine Inhibits the Differentiation and Activation of THP-1 Macrophages through the L-Type Calcium Channel

  2018cites this paper
• Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance?

  2015cites this paper
• Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis

  2015cites this paper
• Opposing roles of nitric oxide and rho-kinase in lipid metabolism in mice.

  2015cites this paper
• Relationship between eNOS 894G>T Polymorphism and the Antihypertensive Efficiency of Two Dihydropyridine Calcium Channel Blocker Drugs, Azelnidipine and Nitrendipine, in Chinese EH Patients

  2015cites this paper
• Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke‐prone spontaneously hypertensive rats

  2014cites this paper
• Rho-Kinase Inhibition Ameliorates Metabolic Disorders through Activation of AMPK Pathway in Mice

  2014cites this paper